Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 8
Submit an article Journal homepage
99
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Infliximab for the treatment of ankylosing spondylitis

M Rudwaleit Charité - Campus Benjamin Franklin, Rheumatology, Department of Medicine I, Hindenburgdamm 30, 12200 Berlin, Germany. [email protected]
&
J Sieper Charité - Campus Benjamin Franklin, Rheumatology, Department of Medicine I, Hindenburgdamm 30, 12200 Berlin, Germany. [email protected]
Pages 1095-1109 | Published online: 24 Nov 2005

Bibliography

  • BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis Rheum. (1998) 41:58–67.
  • GRAN JT, HUSBY G, HORDVIK M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann. Rheum. Dis. (1985) 44:359–367.
  • SARAUX A, GUEDES C, ALLAIN J et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. Rheumatol (1999) 26:2622–2627.
  • LEIRISALO-REPO M: Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum. Dis. Clin. North Am. (1998) 24(4):737–751.
  • SIEPER J, BRAUN J, RUDWALEIT M, BOONEN A. ZINK A: Ankylosing spondylitis: an overview. Ann. Rheum. Dis. (2002) 61 (Suppl. 3):iii8-iii18.
  • BOONEN A: Socioeconomic consequences of ankylosing spondylitis. Clin. Exp. Rheumatol (2002) 20\(Suppl. 28):523–526.
  • LEHTINEN K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann. Rheum. Dis. (1993) 52(3):174–176.
  • MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. (1998) 41:694–700.
  • MUCHE B, BOLLOW M, FRANCOIS RJ, SIEPER J, HAMM B, BRAUN J: Which anatomical structures are involved in early and late sacroiliitis in spondyloarthritis - a detailed analysis by contrast enhanced magnetic resonance imaging. Arthritis Rheum. (2003) 48(5):1374–1384.
  • BRAUN J, BOLLOW M, NEURE L et ell.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499–505.
  • LALOUX L, VOISIN MC, ALLAIN J et ell.: Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (2001) 60:316–321.
  • BOLLOW M, FISCHER T, REISSHAUER H, SIEPER J, HAMM B, BRAUN J: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann. Rheum. Dis. (2000) 59:135–140.
  • DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. j Rheumatol (1999) 26(4):971–974.
  • RUDWALEIT M, NIEWERTH M, LISTING J et al.: Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC). Ann. Rheum. Dis. (2005) 64\(Suppl. 3):65.
  • DOUGADOS M, DIJKMANS B, KHAN M, MAKSYMOWYCH W, VAN DER LINDEN S, BRANDT J: Conventional treatments for ankylosing spondylitis. Ann. Rheum. Dis. (2002) 61\(Suppl. 3):iii40-iii50.
  • AMOR B, DOUGADOS M, KHAN MA: Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum. Dis. Clin. North Am. (1995) 21:117–128.
  • DAGFINRUD H, KVIEN TK, HAGEN KB: Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst. Rev. (2004) 4:CD002822.
  • CHEN J, LIU C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev. (2004) 3:CD004524.
  • HAIBEL H, RUDWALEIT M, BRAUN J, SIEPER J: Six months open label trial of leflunomide in active ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64:124–126.
  • VAN DENDEREN JC, VAN DER PAARDT M, NURMOHAMED MT, DE RYCK YM, DIJKMANS BA, VAN DER HORST-BRUINSMA IE: Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. (2005) (In Press).
  • HAIBEL H, RUDWALEIT M, LISTING J, SIEPER J: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. (2005) 64:296–298.
  • MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. (2002) 46(3):766–773.
  • HAIBEL H, BRANDT J, RUDWALEIT M, SOERENSEN H, SIEPER J, BRAUN J: treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Word) (2003) 42(8):1018–1020.
  • CAIRNS AP, WRIGHT SA, TAGGART AJ, COWARD SM, WRIGHT GD: An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann. Rheum. Dis. (2005) 64(2):338–339.
  • MAERKER-HERMANN E et al.: The burden of disease in patients with ankylosing spondylitis (AS) and pre-radiographic axial spondyloarthritis. Arthritis Rheum. (2004) 50(Suppl.):S211.
  • BRAUN J, SIEPER J: Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. (2002) 4(5):307–321.
  • SCALLON BJ, MOORE MA, TRINH H, KNIGHT DM, GHRAYEB J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 7:251–259.
  • SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol Exp. Ther. (2002) 301:418–426.
  • GRATACOS J, COLLADO A. FILELLAX et al.: Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol (1994) 33(10):927–931.
  • BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. (2000) 43:1346–1352.
  • FELDMANN M, ELLIOTT MJ, WOODY JN et al.: Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv. Immunol (1997) 64:283–350.
  • STONE MA, PAYNE U, PACHECO-TENA C, INMAN RD: Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(1):84–87.
  • BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Thl cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann. Rheum. Dis. (2001) 60(8):750–755.
  • RUDWALEIT M, SIEGERT S, YIN Z et al.: Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann. Rheum. Dis. (2001) 60(1):36–42.
  • ZOU J, RUDWALEIT M, BRANDT J, THIEL A, BRAUN J, SIEPER J: Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. (2003) 48(3):780–790.
  • ZOU J, RUDWALEIT M, BRANDT J, THIEL A, BRAUN J, SIEPER J: Upregulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis. (2003) 62(6):561–564.
  • VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124(7):1774–1785. The induction of apoptosis by infliximab, but not by etanercept, may explain some of the differential effects of the two compounds with respect to both therapeutic efficacy and adverse events.
  • MITOMA H, HORIUCHI T, HATTA N et al.: Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology (2005) 128(2):376–392.
  • YANG C, GU J, RIHL M et al.: Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum. (2004) 51(5):691–699.
  • VANDOOREN B, KRUITHOF E, YU DT et al.: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. (2004) 50(9):2942–2953.
  • BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. (2001) 44:186–195.
  • KRUITHOF E, BAETEN D, VAN DEN BOSCH F, MIELANTS H, VEYS EM, DE KEYSER F: Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann. Rheum. Dis. (2005) 64(4):529–536.
  • MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41(9):1552–1563.
  • MAINI R, ST CLAIR EW, BREED VELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
  • VAN DER HEIJDE D, VAN DER LINDEN S, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA: Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. Rheumatol (1999) 26(4):945–947.
  • VAN DER HEIJDE D, DOUGADOS M, DAVIS J et aL: ASsessment in Ankylosing Spondylitis International Working Group/ Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. (2005) 52(2):386–394.
  • •This article can be used as a guidance for the conduct of clinical trials in AS.
  • GARRETT S, JENKINSON TR, KENNEDY LG, WHITELOCK HC, GAISFORD P, GALIN A: A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J. Rheumatol (1994) 21:2286–2291.
  • BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Treatment of patients with severe ankylosing spondylitis with infliximab - a one year follow up. Arthritis Rheum. (2001) 44(12):2936–2937.
  • BRAUN J, BRANDT J, LISTING J et aL: Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet (2002) 359:1187–1193.
  • ••First placebo-controlled randomised trialwith infliximab in AS, which demonstrated the strong efficacy of infliximab by leading to an improvement in disease activity by at least 50% in half of the patients.
  • VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59:428–433.
  • STONE M, SALONEN D, LAX M, PAYNE U, LAPP V INMAN R: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J. Rheumatol (2001) 28(7):1605–1614.
  • MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al.: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J. Rheumatol (2002) 29:959–965.
  • BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (2002) 41(11):1280–1285.
  • COLLANTES-ESTEVEZ E, MUNOZ-VILLANUEVA MC, CANETE-CRESPILLO JD et al.: Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann. Rheum. Dis. (2003) 62(12):1239–1240.
  • TEMEKONIDIS TI, ALAMANOS Y, NIKAS SN et al: Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann. Rheum. Dis. (2003) 62(12):1218–1220.
  • KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al: Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann. Rheum. Dis. (2002) 61:207–212.
  • VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. (2002) 46:755–765.
  • ••Placebo-controlled trial of infliximab inthe whole group of SpA. This study showed that infliximab is effective not only in AS, but also in other SpA subsets, such as SpA associated with psoriasis, and undifferentiated SpA.
  • VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. (2005) 52(2):582–591.
  • ••The ASSERT trial is the largest(279 patients) placebo-controlled randomised trial of infliximab in AS conducted to date. The clinical response was almost identical to that seen in the first placebo-controlled trial [49].
  • BRAUN J, BRANDT J, LISTING J et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. (2003) 48(8):2224–2233.
  • ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum. (2001) 44:1878–1886.
  • MARZO-ORTEGA H, MCGONAGLE D, JARRETT S et al.: Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann. Rheum. Dis. (2005) (In Press).
  • BRAUN J, BRANDT J, LISTING J et al.: Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(2):229–234.
  • BRAUN J, BARALIAKOS X, BRANDT J et aL: Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (2005) 44:670–676.
  • BARALIAKOS X, LISTING J, BRANDT J, RUDWALEIT M, SIEPER J, BRAUN J: Clinical response to discontinuation of anti-TNF-therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. (2005) 7:R439–R444.
  • •The clinical efficacy of infliximab treatment of active AS is sustained over a period of 3 years. This is of note as no concomitant MTX or other immunosuppressants were given.
  • NIKAS SN, ALAMANOS Y, VOULGARI PV, PLIAKOU XI, PAPADOPOULOS CG, DROSOS AA: Infliximab therapy in ankylosing spondylitis: an observational study. Ann. Rheum. Dis. (2005) 64:940–942.
  • BRAUN J, BARALIAKOS X, GOLDER W et al.: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. (2003) 48(4):1126–1136.
  • ••First study showing that infliximab notonly improves clinical signs and symptoms, but also leads to a significant decrease of active inflammatory lesions in the spine as detectable by MRI.
  • BARALIAKOS X, LISTING J, RUDWALEIT M, BRANDT J, SIEPER J, BRAUN J: Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-a antibody infliximab. Ann. Rheum. Dis. (2005) (In Press).
  • D'AGOSTINO MA, BREBAN M, SAID-NAHAL R, DOUGAODS M: Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. (2002) 46:840–841.
  • ALLALI F, BREBAN M, PORCHER R, MAILLEFERT JF, DOUGADOS M, ROUX C: Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann. Rheum. Dis. (2003) 62(4):347–349.
  • DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. (1995) 38(5):618–627.
  • BENITEZ-DEL-CASTILLO JM, GARCIA-SANCHEZ J, IRADIER T, BANARES A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (2000) 14:340–343.
  • EL-SHABRAWI Y, HERMANN J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology (2002) 109(12):2342–2346.
  • SMITH JR, LEVINSON RD, HOLLAND GN et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. (2001) 45(3):252–257.
  • KRUITHOF E, KESTELYN P, ELEWAUT C et al.: Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann. Rheum. Dis. (2002) 61(5):470.
  • FRIES W, GIOFRE MR, CATANOSO M, LO GR: Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am. J. Gastroenterol (2002) 97(2):499–500.
  • ANTONI C, BRAUN J: Adverse events of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol (2002) 20(6 Suppl. 28):5152–5157.
  • KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl. J. Med. (2001) 345(15):1098–1104.
  • WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. (2004) 50(2):372–379.
  • GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD; BIOBADASER GROUP: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. (2003) 48(8):2122–2127.
  • BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann. Rheum. Dis. (2003) 62(9):829–834.
  • ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. (2003) 48(11):3013–3022.
  • HYRICH KL, SILMAN AJ, WATSON KD, SYMMONS DP: Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. (2004) 63(12):1538–1543.
  • WALLIS RS, BRODER MS, WONG JY HANSON ME, BEENHOUVER DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. (2004) 38:1261–1265.
  • BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46(12):3151–3158.
  • WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50(6):1740–1751.
  • GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann. Rheum. Dis. (2005) 64(5):699–703.
  • MOHAN N, EDWARDS ET, CUPOS TR et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44(12):2862–2869.
  • DAVIS JC JR, VAN DER HEIJDE D, BRAUN J et al.: Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. (2003) 48(11):3230–3236.
  • ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86(2-3):123–130.
  • CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107(25):3133–3140.
  • KWON HJ, COTE TR, CUFFE MS, KRAMER JM, BRAUN MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138(10):807–811.
  • WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116(5):305–311.
  • CHARLES PJ, SMEENK RJ, DE JONG J,FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43(11):2383–2390.
  • DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. (2003) 48(4):1015–1023.
  • HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541–1548.
  • FERRARO-PEYRET C, COURY F, TEBIB JG, BIENVENU J, FABIEN N: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res. Ther. (2004) 6(6):R535–R543.
  • JARRETT SJ, CUNNANE G, CONAGHAN PG et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J. Rheumatol (2003) 30(10):2287–2291.
  • CHEIFETZ A, SMEDLEY M, MARTIN Set al: The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol (2003) 98(6):1315–1324.
  • •Comprehensive description of the frequency, severity and management of infusion reactions that may occur in patients recieving infliximab.
  • FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-lra), for the treatment of rheumatic diseases, 2004. Ann. Rheum. Dis. (2004) 63\(Suppl. 2):ii2-ii12.
  • HAIBEL H, SPILLER I, STRASSER C, RUDWALEIT M, DORNER T, SIEPER J: Unexpected new onset or exacerbation of psoriasis in treatment of ankylosing spondylitis with the TNF-alpha blocking agents: four case reports. Ann. Rheum. Dis. (2004) 63\(Suppl. 1):405.
  • MICHEL M, DUVOUX C, HEZODE C, CHERQUI D: Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. Rheumatol (2003) 30(7):1624–1625.
  • WENDLING D, AUGE B, BETTINGER D et al.: Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. (2005) 64(5):788–789.
  • CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. (2004) 63(Suppl.
  • LISTING J, BRANDT J, RUDWALEIT M, ZINK A. SIEPER J, BRAUN J: Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(12):1670–1672.
  • KOBELT G, ANDLING-SOBOCKI P, BROPHY S, JONSSON L, CALIN A, BRAUN J: The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (2004) 43(9):1158–1166.
  • KATZ JA, ANTONI C, KEENAN GF, SMITH DE, JACOBS SJ, LICHTENSTEIN GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol (2004) 99(12):2385–2392.
  • CHEROUVIM EP, ZINTZARAS E, BOKI KA, MOUTSOPOULOS HM, MANOUSSAKIS MN: Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3mg/kg: a 20-month open treatment. J. Clin. Rheumatol (2004) 10(4):162–168.
  • BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor a monoclonal antibody infliximab. j Rheumatol (2002) 29:118–122.
  • ST CLAIR EW, WAGENER CL, FASANMADE AA et al: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(6):1451–1459.
  • BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J. Med. (2003) 348:601–608.
  • SANDBORN WJ, HANAUER SB, KATZ S et al: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088–1094.
  • MIELANTS H, VEYS EM, CUVELIER C, DE VOS M: Ileocolonoscopic findings in seronegative spondylarthropathies. Br. J. Rheumatol. (1988) 27\(Suppl. 2):95–105.
  • BRANDT J, KHARIOUZOV A, LISTING J et al: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. (2003) 48(6):1667–1675.
  • MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann. Rheum. Dis. (2003) 62(1):74–76.
  • GOTTLIEB AB, MATHESON RT, LOWE N et al.: A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol (2003) 139(12):1627–1632.
  • MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
  • ANTONI C, KRUEGER GG, DE VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. (2005) 64(8):1150–1157.
  • GOTTLIEB AB, EVANS R, LI S et al: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol (2004) 51(4):534–542.
  • RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63:665-670. First indication that a short disease duration (likely to reflect active inflammation when compared with late disease at the group level) is associated with a good clinical response to infliximab.
  • BRAUN J, PHAM T, SIEPER J et ed.; ASAS WORKING GROUP: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2003) 62(9):817–824.
  • RUDWALEIT M, VAN DER HEIJDE D, KHAN MA, BRAUN J, SIEPER J: How to diagnose axial spondyloarthritis early. Ann. Rheum. Dis. (2004) 63(5):535–543.
  • RUDWALEIT M, KHAN MA, SIEPER J: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. (2005) 52:1000–1008.
  • VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. (1984) 27(4):361–368.

Websites

  • http://www.observatoire-ratio.org Observatoire RATIO website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.